Shareholder Alert: Robbins LLP Informs Investors of Class Action Against ImmunityBio, Inc. (IBRX)

SAN DIEGO–(BUSINESS WIRE)–$IBRX #Anktiva–Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between May 23, 2022 and May 10, 2023. ImmunityBio is a clinical-stage biotechnology company that develops therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. One of ImmunityBio’s key products is Anktiva, for which it uses a third-party contract manufacturing organization (“CMO”) to produce.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: ImmunityBio, Inc. (IBRX) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate
According to the complaint, ImmunityBio submitted a Biologics License Application (“BLA”) for Anktiva to the U.S. Food and Drug Administration (“FDA”). However, during the class period, defendants failed to disclose that (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, Good Manufacturing Practice (“GMP”) deficiencies at its third-party CMOs for Anktiva; (ii) one or more of the Company’s third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies were likely to cause the FDA to reject the Anktiva BLA in its present form; and (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA.
On May 11, 2023, ImmunityBio announced that the FDA had rejected the BLA for Anktiva, citing “deficiencies relat[ing] to the FDA’s pre-license inspection of the Company’s third-party contract manufacturing organizations.” On this news, ImmunityBio’s stock price fell $3.43 per share, or over 55%, to close at $2.79 per share on May 11, 2023.
What Now: Similarly situated shareholders may be eligible to participate in the class action against ImmunityBio, Inc. Shareholders who want to act as lead plaintiff for the class must file their motion with the court by August 29, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.
To be notified if a class action against ImmunityBio, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome. Contacts
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com(800) 350-6003
www.robbinsllp.com